Positive Results Observed in Family Caregivers of Patients with Lung Cancer After Interventions
the Cancer Therapy Advisor take:
Family caregivers (FCGs) who received an interdisciplinary palliative care intervention reported greater social well-being and less psychological distress and caregiver burden compared to those in the usual care cohort, according to an article published online in the journal Cancer.
Patients diagnosed with stage 1 through 4 non-small cell lung cancer identified primary FCGs who then took part in this study. Two groups were identified: the usual care group and the intervention cohort.
FCGs in the palliative care intervention group were presented at interdisciplinary care meetings and attended four educational sessions of physical, psychological, social, and spiritual domains. In the sessions, FCGs were supported through self-care plans.
At the beginning of the study and again 12 weeks later, FCGs were evaluated regarding caregiver burden, caregiving skills preparedness, psychological distress, and quality of life.
After 12 weeks in the palliative care intervention group, FCGs had increased scores of social well-being (5.84 vs. 6.86; P<0.001) and reduced scores of psychological distress (4.61 vs. 4.20; P=0.010), compared to those in the usual care group.
Results also showed that FCGs of patients with lung cancer in the interdisciplinary intervention group experienced significantly less caregiver burden than FCGs in the usual care cohort (P=0.008).
Family caregivers who received interdisciplinary palliative care intervention reported greater social well-being and less psychological distress.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma